Tandem Diabetes Care Q4 2022 Earnings Report

Tandem Diabetes Care EPS Results

• Actual EPS: -$0.01
• Consensus EPS: -$0.02
• Beat/Miss: Beat by +$0.01
• One Year Ago EPS: $0.16

Tandem Diabetes Care Revenue Results

• Actual Revenue: $223.45 million
• Expected Revenue: $221.99 million
• Beat/Miss: Beat by +$1.46 million
• YoY Revenue Growth: +6.40%

Tandem Diabetes Care Announcement Details

• Quarter: Q4 2022
• Date: 2/22/2023
• Time: After Market Closes

Tandem Diabetes Care (NASDAQ:TNDM), a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.